Sight Sciences Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Paul Badawi
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 21.18% |
| CEO tenure | 15yrs |
| CEO ownership | 11.3% |
| Management average tenure | 2.7yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Dec 31Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry?
Nov 13
Market Participants Recognise Sight Sciences, Inc.'s (NASDAQ:SGHT) Revenues Pushing Shares 37% Higher
Oct 18Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet?
Aug 09Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement
May 14
OMNIEdge And TearCare Will Transform MIGS Treatments
Strategic initiatives, such as the OMNIEdge launch and positive reimbursement for TearCare, aim to capture market share and improve revenue and margins.Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 30Is Sight Sciences (NASDAQ:SGHT) Using Debt Sensibly?
Jan 17Sight Sciences, Inc. (NASDAQ:SGHT) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
Nov 13Why We're Not Concerned Yet About Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge
Aug 15Is Sight Sciences (NASDAQ:SGHT) A Risky Investment?
Jul 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$46m |
| Jun 30 2025 | n/a | n/a | -US$49m |
| Mar 31 2025 | n/a | n/a | -US$49m |
| Dec 31 2024 | US$3m | US$640k | -US$52m |
| Sep 30 2024 | n/a | n/a | -US$50m |
| Jun 30 2024 | n/a | n/a | -US$52m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$4m | US$610k | -US$56m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$71m |
| Mar 31 2023 | n/a | n/a | -US$80m |
| Dec 31 2022 | US$6m | US$580k | -US$86m |
| Sep 30 2022 | n/a | n/a | -US$85m |
| Jun 30 2022 | n/a | n/a | -US$80m |
| Mar 31 2022 | n/a | n/a | -US$74m |
| Dec 31 2021 | US$9m | US$424k | -US$63m |
| Sep 30 2021 | n/a | n/a | -US$56m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$497k | US$360k | -US$35m |
Compensation vs Market: Paul's total compensation ($USD3.02M) is about average for companies of similar size in the US market ($USD2.33M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Badawi (50 yo)
Mr. Paul Badawi is a Co-Founder of Sight Sciences, Inc. since 2011 and serves as its President and Chief Executive Officer since 2011. Mr. Badawi specializes in medical technology investments for 3i. His p...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15yrs | US$3.02m | 11.28% $ 47.3m | |
| Co-Founder | 15yrs | no data | 3.64% $ 15.3m | |
| COO & Principal Operation Officer | less than a year | US$2.24m | 0.26% $ 1.1m | |
| Chief Legal Officer & Corporate Secretary | 5.8yrs | US$1.48m | 0.49% $ 2.0m | |
| CFO, Principal Financial Officer | less than a year | no data | 0.049% $ 204.1k | |
| VP and Chief Ethics & Compliance Officer | 2.7yrs | no data | no data | |
| Executive Vice President of Operations and R&D | no data | no data | 0.050% $ 211.0k | |
| Senior Vice President of Glaucoma | 1yr | no data | no data |
Experienced Management: SGHT's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15yrs | US$3.02m | 11.28% $ 47.3m | |
| Co-Founder | 15yrs | no data | 3.64% $ 15.3m | |
| Independent Director | less than a year | no data | 0.038% $ 158.6k | |
| Independent Director | 5.5yrs | US$187.50k | 0.25% $ 1.1m | |
| Independent Chairman | 8.3yrs | US$213.50k | 3.77% $ 15.8m | |
| Independent Director | 3.5yrs | US$175.00k | 0.084% $ 352.4k | |
| Independent Director | 2.6yrs | US$182.00k | 0% $ 0 |
Experienced Board: SGHT's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 15:58 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sight Sciences, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Joanne Wuensch | Citigroup Inc |
| Frank Takkinen | Lake Street Capital Markets, LLC |